The US Food & Drug Administration (FDA) has issued an alert about overdoses, some requiring hospital admission, after patient and physician confusion around compounded semaglutide.
Adverse events reported to the agency have ranged from gastrointestinal events like nausea, vomiting and abdominal pain – the most common side effects with GLP-1 receptor agonists – to fainting, headache, migraine, dehydration, acute pancreatitis and gallstones.
While FDA-approved injectable semaglutide (Ozempic, Wegovy) is dosed in milligrams and is available only in prefilled pens, compounded semaglutide can come in varying concentrations (depending on the compounder or even by the same compounder) and uses multiple-dose vials.
Medpage Today reports that both patients’ incorrect self-administration and healthcare providers’ dose miscalculations have been at play.
The FDA said that many of the patients who received vials of compounded semaglutide “lacked experience with self-injections”, according to the adverse event reports.
“Unfamiliarity with withdrawing medication from a vial into a syringe and coupled with confusion between different units of measurement (e.g, millilitres, milligrams and ‘units’) may have contributed to dosing errors.”
In some cases, patients have administered five- to 20-times more than the intended dose of semaglutide after mistakenly drawing up more than the prescribed dose from a multiple-dose vial.
As noted in several reports, patients were instructed to use a U-100 (1 mL) insulin syringe to draw up small doses like a five-unit (0.05 mL) dose but mistakenly administered 50 units instead.
“In one reported case, it was difficult for the patient to obtain clarity on dosing instructions from the telemedicine provider, who had prescribed the compounded semaglutide, leading the patient to conduct an online search for medical advice and then take five times the intended dose,” the FDA added.
Other reports described how healthcare providers were responsible for incorrectly calculating the intended dose when converting from milligrams to units or millilitres, leading to doses five- to 10-times higher than the intended dose.
For example, one healthcare provider intended to dose 0.25 mg (five units) but accidentally prescribed 25 units instead.
Another healthcare provider prescribed 20 units instead of two units to three patients, all of whom later experienced nausea and vomiting. One healthcare provider who self-prescribed the drug tried to recalculate their own dose in units and accidentally self-administered a dose 10 times higher than intended.
The FDA said healthcare providers should “be vigilant” when prescribing compounded semaglutide and to contact the compounder about calculating the dose if there is any uncertainty. Providers and compounders should also give patients the appropriate syringe size for the intended dose and teach patients how to measure the intended dose using the syringe.
Compounded semaglutide has grown in popularity over the past few years due to the spike in demand for GLP-1 receptor agonists that led to supply and access issues.
But, the FDA said, compounded drugs should only be used for patients whose medical needs cannot be met by an available FDA-approved drug.
Compared with Novo Nordisk’s branded semaglutide, compounded versions can pose higher risks to patients because they don’t undergo the same FDA premarket review for safety, quality, or effectiveness.
Novo Nordisk has taken legal action on compounded semaglutide. One review found high levels of known impurities and the presence of unknown impurities in some compounded products, while another consisted of more than 24% impurities, including unknown ones.
Medpage Today article – FDA Warns of Overdoses With Compounded Semaglutide (Open access)
See more from MedicalBrief archives:
Fake Ozempic sends users to hospitals
US study finds serious side effects from weight-loss drugs